NYSE : NUVB
Nuvation Bio Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 4.77 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.67B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.67B |
| Enterprise Value | 1.43B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 350.12M |
| Shares Outstanding | 351.12M |
| Shares Change (YoY) | +4.49% |
| Shares Change (QoQ) | +0.41% |
| Owned by Insiders (%) | 17.52% |
| Owned by Institutions (%) | 60.01% |
| Float | 263.65M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.84 |
| Forward PS | 8.19 |
| PB Ratio | 6.56 |
| P/TBV Ratio | 6.86 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 8.40 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 8.37 |
| Quick Ratio | 7.98 |
| Debt / Equity | 1.64 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.16 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -47.81% |
| Return on Assets (ROA) | -12.36% |
| Return on Invested Capital (ROIC) | -13.80% |
| Return on Capital Employed (ROCE) | -20.92% |
| Weighted Average Cost of Capital (WACC) | 11.53% |
| Revenue Per Employee | $557,049 |
| Profits Per Employee | -$491,236 |
| Employee Count | 305 |
| Asset Turnover | 0.24 |
| Inventory Turnover | 1.96 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.62 |
| 52-Week Price Change | -9.51% |
| 50-Day Moving Average | 5.63 |
| 200-Day Moving Average | 5.40 |
| Relative Strength Index (RSI) | 42.24 |
| Average Volume (20 Days) | 5,410,074 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 63.22M |
| Short Previous Month | 58.17M |
| Short % of Shares Out | 18.01% |
| Short % of Float | 23.98% |
| Short Ratio (days to cover) | 11.57 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 169.90M |
| Gross Profit | 149.81M |
| Operating Income | -137.63M |
| Pretax Income | -149.83M |
| Net Income | -149.83M |
| EBITDA | -135.48M |
| EBIT | -137.63M |
| Loss Per Share | -$0.44 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 660.96M |
| Total Debt | 416.26M |
| Net Cash | 244.69M |
| Net Cash Per Share | $0.70 |
| Equity (Book Value) | 253.86M |
| Book Value Per Share | 0.73 |
| Working Capital | 639.68M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -120.52M |
| Capital Expenditures | -403,000 |
| Depreciation & Amortization | 2.15M |
| Net Borrowing | 182.69M |
| Free Cash Flow | -120.93M |
| FCF Per Share | -$0.34 |
Margins
| Measure | Value |
|---|
| Gross Margin | 88.18% |
| Operating Margin | -81.00% |
| Pretax Margin | -88.19% |
| Profit Margin | -88.19% |
| EBITDA Margin | -79.74% |
| EBIT Margin | -81.00% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -4.49% |
| Shareholder Yield | -4.49% |
| Earnings Yield | -9.22% |
| FCF Yield | -7.24% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $13.00 |
| Price Target Difference | 173.11% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | 88.55% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 0.48 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |